A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)
A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Three Doses of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Spasticity in Participants With Multiple Sclerosis (BALANCE-MSS-1)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Birmingham, Alabama 35209, United States
205-803-2210
Philadelphia, Pennsylvania 19107, United States
Sydney, New South Wales 2050, Australia
Münster, North Rhine-Westphalia 48149, Germany
602-258-3368
239-529-6780
813-974-6378
913-588-6980
781-551-5812
314-362-3293
412-427-7087
614-566-1255
215-955-6871
865-218-6222
425-899-5385
+61 2 4042 0682
+61 2 9351 0704
+61 8 81320494
+61 3 9094 9527
+61 3 94963705
+ 61 3 93429092
+61 8 6457 0213
780-248-5895
519 685 8500x35520
613-737-8104
416-864-6060 x3450
418-780-3501x2703
(514) 396-2950
+420 543 182 658
+420 495 831 111
+420 224 961 111
+420 543 182 658
+420 466 014 732
+420 417 519 625
00499313935700
004956171611
00492345092441
00492518348165
+4936419323486
0049521443069
+4917610315216
0048698619497
+48122954100
+48607685751
+48-501-485-317
+48660517184
665041418
787-930-1705